BioCentury
ARTICLE | Finance

Public-Private Partnership Roundup

Highlights of public-private partnerships from 1Q16

April 28, 2016 7:00 AM UTC

Public-private partnerships (PPPs) continue to accumulate at a high rate in the preclinical space, with 56 deals disclosed in 1Q16, but the data suggest the nature of the deals is moving away from large disease-centric multiparty consortia and towards deals focused on organizations' specific programs.

Only 11 deals involved big pharmas or biotechs, compared with 20 during 1Q15. Johnson & Johnson tallied six deals, half from its Janssen Research & Development LLC unit (see Figure: New PPPs 1Q16). Additionally, the appetite for consortia - defined by BioCentury Innovations as partnerships involving four or more organizations - may have continued to tail off, with just three new ones announced during the first quarter, compared with four in the first quarter of 2015 and 20 all last year (see Figure: PPPs Around the World). ...